Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06297603 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Dec 23, 2025, no change to tracked fieldsv24-v25
  2. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Sep 2026 to Oct 2026 · Completion date: Oct 2026 to Nov 2026 · Site details revised at 76 of 76 sitesv23 Show 3 more changesShow less
    • Primary completion date: Sep 2026 to Oct 2026
    • Completion date: Oct 2026 to Nov 2026
    • Site details revised at 76 of 76 sites
  3. Study sites: 79 to 76v22
  4. Site contacts updated at 1 of 79 sitesv21
  5. Site details revised at 4 of 79 sitesv20
Show 18 earlier versionsHide 18 earlier versions
  1. Site details revised at 1 of 79 sitesv19
  2. Site details revised at 39 of 79 sitesv18
  3. Site details revised at 2 of 79 sitesv17
  4. Site details revised at 4 of 79 sitesv16
  5. Study sites: 80 to 79v15
  6. Study sites: 81 to 80v14
  7. Site details revised at 4 of 81 sitesv13
  8. Study sites: 79 to 81v12
  9. Study sites: 76 to 79v11
  10. Study sites: 61 to 76v10
  11. Study sites: 49 to 61 Primary completion date: Sep 11, 2026 to Sep 2026 · Completion date: Oct 9, 2026 to Oct 2026v9 Show 2 more changesShow less
    • Primary completion date: Sep 11, 2026 to Sep 2026
    • Completion date: Oct 9, 2026 to Oct 2026
  12. Site details revised at 3 of 49 sitesv8
  13. Study sites: 48 to 49v7
  14. Study sites: 44 to 48v6
  15. Study sites revised (44)v5 See this version in full on ClinicalTrials.gov ↗
  16. Site details revised at 3 of 44 sitesv4
  17. Study sites: 39 to 44v3
  18. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 12, 2024 to Mar 15, 2024 · Site details revised at 39 of 39 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Apr 12, 2024 to Mar 15, 2024
    • Site details revised at 39 of 39 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
359 trials monitored
See 15 trials at risk
Diabetes
4,286 trials monitored
See 187 trials at risk
Type 2 Diabetes
2,100 trials monitored
See 102 trials at risk
Chronic Kidney Disease
1,327 trials monitored
See 59 trials at risk
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Trial Details
NCT Number NCT06297603
Lead Sponsor Eli Lilly and Company
Conditions Type 2 Diabetes
Enrollment 320 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov